识别脓毒症中的炎症表型，以针对特定机制的治疗方法。
Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis.
机构信息
Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Surgery, Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
出版信息
Cell Rep Med. 2022 Nov 15;3(11):100823. doi: 10.1016/j.xcrm.2022.100823.
Abstract
A clinical trial by Leventogiannis et al. suggests that ferritin and HLA-DR monocyte receptor expression can identify septic patients with macrophage-activation-like syndrome (MALS), or immunoparalysis, and that targeting IL-1ra treatment with this strategy may improve outcomes.
摘要
列凡托吉安尼斯等人的一项临床试验表明，铁蛋白和 HLA-DR 单核细胞受体表达可识别出具有巨噬细胞活化样综合征（MALS）或免疫麻痹的脓毒症患者，并且通过这种策略靶向白细胞介素 1 受体拮抗剂（IL-1ra）治疗可能改善预后。
相似文献
1
Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis.识别脓毒症中的炎症表型，以针对特定机制的治疗方法。
Cell Rep Med. 2022 Nov 15;3(11):100823. doi: 10.1016/j.xcrm.2022.100823.
2
Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.迈向脓毒症个体化免疫治疗：PROVIDE 随机临床试验。
Cell Rep Med. 2022 Nov 15;3(11):100817. doi: 10.1016/j.xcrm.2022.100817.
3
Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis.巨噬细胞活化综合征：导致脓毒症早期死亡的独特实体。
Front Immunol. 2019 Jan 31;10:55. doi: 10.3389/fimmu.2019.00055. eCollection 2019.
4
[Monocyte HLA-DR expression as predictors of clinical outcome for patients with sepsis].[单核细胞人类白细胞抗原-DR表达作为脓毒症患者临床结局的预测指标]
Nihon Rinsho. 2004 Dec;62(12):2281-4.
5
Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber.使用多粘菌素B固定化纤维血液灌流对感染性休克患者单核细胞上人类白细胞抗原-DR及粒细胞上CD16的调节作用。
Am J Surg. 2004 Aug;188(2):150-6. doi: 10.1016/j.amjsurg.2003.12.067.
6
[Immunological monitoring of sepsis using flow cytometry--quantitation of monocyte HLA-DR expression and granulocyte CD64 expression].[采用流式细胞术对脓毒症进行免疫监测——单核细胞HLA-DR表达及粒细胞CD64表达的定量分析]
Epidemiol Mikrobiol Imunol. 2005 Apr;54(2):54-61.
7
Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?低单核细胞 HLA-DR 表达有助于预测严重脓毒症的预后吗？
Intensive Care Med. 2003 Aug;29(8):1245-52. doi: 10.1007/s00134-003-1686-2. Epub 2003 May 28.
8
Immunoparalysis: Clinical and immunological associations in SIRS and severe sepsis patients.免疫麻痹：全身炎症反应综合征和严重脓毒症患者的临床及免疫学关联
Cytokine. 2017 Apr;92:83-92. doi: 10.1016/j.cyto.2017.01.012. Epub 2017 Jan 21.
9
[Clinical trial to verify the value of the CD14(+) monocyte human leukocyte antigen DR as a marker in evaluating immunosuppression in patients with severe sepsis].[验证CD14(+)单核细胞人类白细胞抗原DR作为评估严重脓毒症患者免疫抑制标志物价值的临床试验]
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Mar;15(3):135-8.
10
Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis.脓毒症患者树突状细胞亚群表型改变及功能障碍：一项前瞻性观察性分析。
Crit Care. 2009;13(4):R119. doi: 10.1186/cc7969. Epub 2009 Jul 15.
引用本文的文献
1
Evolving Paradigms in Sepsis Management: A Narrative Review.脓毒症管理的范式转变：叙事性综述。
Cells. 2024 Jul 9;13(14):1172. doi: 10.3390/cells13141172.
2
The Omics Complexity in Sepsis: The Limits of the Personalized Medicine Approach.脓毒症中的组学复杂性：个性化医疗方法的局限性
J Pers Med. 2024 Feb 20;14(3):225. doi: 10.3390/jpm14030225.
3
Multi-Omics Endotypes in ICU Sepsis-Induced Immunosuppression.重症监护病房中脓毒症诱导的免疫抑制的多组学内型
Microorganisms. 2023 Apr 25;11(5):1119. doi: 10.3390/microorganisms11051119.
本文引用的文献
1
Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.迈向脓毒症个体化免疫治疗：PROVIDE 随机临床试验。
Cell Rep Med. 2022 Nov 15;3(11):100817. doi: 10.1016/j.xcrm.2022.100817.
2
Methods for Phenotyping Adult Patients in Sepsis and Septic Shock: A Scoping Review.脓毒症和脓毒性休克成年患者的表型分析方法：一项范围综述
Crit Care Explor. 2022 Mar 30;4(4):e0672. doi: 10.1097/CCE.0000000000000672. eCollection 2022 Apr.
3
Sepsis with liver dysfunction and coagulopathy predicts an inflammatory pattern of macrophage activation.伴有肝功能障碍和凝血病的脓毒症预示着巨噬细胞激活的炎症模式。
Intensive Care Med Exp. 2022 Feb 21;10(1):6. doi: 10.1186/s40635-022-00433-y.
4
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.新型败血症临床表型的推导、验证及潜在治疗意义。
JAMA. 2019 May 28;321(20):2003-2017. doi: 10.1001/jama.2019.5791.
5
Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis.巨噬细胞活化样综合征：一种与脓毒症快速进展至死亡相关的免疫实体。
BMC Med. 2017 Sep 18;15(1):172. doi: 10.1186/s12916-017-0930-5.
6
Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study.根据血液基因组内型对脓毒症患者进行分类：一项前瞻性队列研究。
Lancet Respir Med. 2017 Oct;5(10):816-826. doi: 10.1016/S2213-2600(17)30294-1. Epub 2017 Aug 29.
7
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.致命性 NLRC4 相关过度炎症经 IL-18 抑制治疗成功。
J Allergy Clin Immunol. 2017 May;139(5):1698-1701. doi: 10.1016/j.jaci.2016.10.022. Epub 2016 Nov 19.
8
Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.败血症患者个体宿主反应和结局的基因组图谱：一项前瞻性队列研究。
Lancet Respir Med. 2016 Apr;4(4):259-71. doi: 10.1016/S2213-2600(16)00046-1. Epub 2016 Feb 23.
9
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.白细胞介素-1受体阻断与具有巨噬细胞活化综合征特征的脓毒症患者死亡率降低相关：对一项既往III期试验的重新分析
Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.
10
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.严重脓毒症中白细胞介素-1受体拮抗剂的验证性试验：一项III期、随机、双盲、安慰剂对照、多中心试验。白细胞介素-1受体拮抗剂脓毒症研究组。
Crit Care Med. 1997 Jul;25(7):1115-24. doi: 10.1097/00003246-199707000-00010.
Zotero 插件